Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials
- PMID: 11211013
- DOI: 10.1016/S0140-6736(00)03651-5
Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials
Abstract
This two-part review is intended principally for practising clinicians who want to know why some types of evidence about the effects of treatment on survival, and on other major aspects of chronic disease outcome, are much more reliable than others. Although there are a few striking examples of treatments for serious disease which really do work extremely well, most claims for big improvements turn out to be evanescent. Unrealistic expectations about the chances of discovering large treatment effects could misleadingly suggest that evidence from small randomised trials or from non-randomised studies will suffice. By contrast, the reliable assessment of any more moderate effects of treatment on major outcomes--which are usually all that can realistically be expected from most treatments for most common serious conditions--requires studies that guarantee both strict control of bias (which, in general, requires proper randomisation and appropriate analysis, with no unduly data-dependent emphasis on specific parts of the overall evidence) and strict control of random error (which, in general, requires large numbers of deaths or of some other relevant outcome). Past failures to produce such evidence, and to interpret it appropriately, have already led to many premature deaths and much unnecessary suffering.
Similar articles
-
"Just Another Statistic".Oncologist. 1998;3(3):III-IV. Oncologist. 1998. PMID: 10388105
-
Procedures and methods of benefit assessments for medicines in Germany.Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5. Eur J Health Econ. 2008. PMID: 18987905
-
Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies.Lancet. 2001 Feb 10;357(9254):455-62. doi: 10.1016/S0140-6736(00)04017-4. Lancet. 2001. PMID: 11273081 Review.
-
How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?Annu Rev Pharmacol Toxicol. 2015;55:169-89. doi: 10.1146/annurev-pharmtox-010814-124614. Epub 2014 Aug 21. Annu Rev Pharmacol Toxicol. 2015. PMID: 25149917
-
Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology.Cardiol J. 2011;18(1):3-7. Cardiol J. 2011. PMID: 21305479 Review.
Cited by
-
Old drugs for a new indication: a review of chloroquine and analogue in COVID-19 treatment.Porto Biomed J. 2021 Jun 14;6(3):e132. doi: 10.1097/j.pbj.0000000000000132. eCollection 2021 May-Jun. Porto Biomed J. 2021. PMID: 34136717 Free PMC article. Review.
-
Clinical trials are too often founded on poor quality pre-clinical research.J Neurol. 2005 Sep;252(9):1115. doi: 10.1007/s00415-005-0803-2. Epub 2005 Mar 24. J Neurol. 2005. PMID: 15789130 Review. No abstract available.
-
What's new in trial design: propensity scores, equivalence, and non-inferiority.J Extra Corpor Technol. 2009 Dec;41(4):P6-10. J Extra Corpor Technol. 2009. PMID: 20092080 Free PMC article.
-
Statin Use in Patients With Chronic Liver Disease and Cirrhosis: Current Evidence and Future Directions.Gastroenterology Res. 2022 Feb;15(1):1-12. doi: 10.14740/gr1498. Epub 2022 Feb 25. Gastroenterology Res. 2022. PMID: 35369681 Free PMC article. Review.
-
Evidence-based medicine and psychiatric practice.Psychiatr Q. 2003 Winter;74(4):387-99. doi: 10.1023/a:1026091611425. Psychiatr Q. 2003. PMID: 14686461
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous